Clinical Trial Update: Mechanistic Study of EBV mRNA Vaccine (WGc-043) in EBV-Positive Relapsed/Refractory Lymphoma

View source ↗

Summary

A mechanistic study of the Epstein-Barr virus mRNA vaccine WGc-043 in EBV-positive relapsed/refractory lymphoma; the trial is not yet recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Epstein-barr Virus Associated Lymphoma

Drugs mentioned

• WGc-043 EBV mRNA vaccine

Snippet

Sponsor: Ruijin Hospital | Conditions: Epstein-Barr Virus Associated Lymphoma | Status: NOT_YET_RECRUITING